Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LT2011 who wrote (11268)	5/14/2012 6:33:30 PM
From: jm2i123	Respond to of 13111

27 US patent. what a chap.

To: LT2011 who wrote (11268)	5/14/2012 7:50:39 PM
From: Littlebits	Respond to of 13111

I doubt his executive powers have been diminished, but not sure. Most likely the importance of the IP and the vigilance In that area grows exceedingly important in the future.

To: LT2011 who wrote (11268)	5/15/2012 6:01:33 AM
From: NTTG	1 Recommendation Read Replies (2) \| Respond to of 13111

While positioning to secure a development partner PVCT has to recognize that the partner will have a much stronger clinical development track record than PVCT does. They would likely want direct control over the development process moving forward (i.e. how their money is being spent). Eric is not that person, probably one of many key learnings during discussion with the FDA. The new position can be designed any way the company desires, I would guess 'disposability' will be one of the features... Eric, time to buy more shares if you want to stay in the game?